PubAg

Main content area

Derivatization of (5R)-hydroxytriptolide from benzylamine to enhance mass spectrometric detection: Application to a Phase I pharmacokinetic study in humans

Author:
Liu, Jia, Chen, Xiaoyan, Zhang, Yifan, Miao, Hong, Liu, Ke, Li, Liang, Zhong, Dafang
Source:
Analytica chimica acta 2011 v.689 no.1 pp. 69-76
ISSN:
0003-2670
Subject:
acetonitrile, ammonium hydroxide, anti-inflammatory activity, clinical trials, derivatization, humans, ionization, liquid chromatography, pH, pharmacokinetics, solvents, tandem mass spectrometry
Abstract:
(5R)-Hydroxytriptolide, a semisynthetic structural analog of triptolide, exhibits anti-inflammatory and immunosuppressive effect both in vitro and in vivo. The compound is currently undergoing Phase I clinical trials. This work describes the quantification of (5R)-hydroxytriptolide in human plasma based on chemical derivatization from benzylamine. Analysis through liquid chromatography–tandem mass spectrometry (LC–MS/MS) is performed for characterization. The primary reaction product between (5R)-hydroxytriptolide and benzylamine was identified as a 12,13-epoxide ring adduct. For quantification in plasma, (5R)-hydroxytriptolide and the internal standard (triptolide) were first extracted from diethyl ether–dichloromethane (3:2, v/v) and then converted to their benzylamine derivates at 80°C for 1h. The analytes are separated on a Gemini 5μm 100Å column, using a gradient elution program with a solvent consisting of 0.77mM ammonium hydroxide (pH 10.0) and acetonitrile. An API 4000 tandem mass spectrometer operated in positive ion mode and equipped with an electrospray ionization source is used as detector. This method allows for a lower limit of quantification of 0.030ngmL⁻¹. The validation results show accuracy (%RE<11.7) and precision (%RSD<8.6) at a broad linear dynamic range (0.030–100ngmL⁻¹). The simple and quantitative derivatization coupled with tandem mass spectrometric analysis yields a sensitive and robust method for the quantification of (5R)-hydroxytriptolide in Phase I pharmacokinetic studies.
Agid:
856898